Therapy for XXXX : impact of @entity632 -based therapy.

@entity1 @entity632 @entity0 @entity5 @entity229 @entity786 @entity1891 @entity1499 @entity1487
BACKGROUND: @entity0 ( @entity0 ) carries an ominous prognosis. Before 1988, @entity1 with @entity0 at our institution were treated with neoadjuvant @entity786 , @entity1499 , and @entity1487 (CMF) with or without @entity1891 and @entity229 (CMF/VP). After 1988, @entity1 with @entity0 were treated with @entity786 , @entity632 , and @entity1487 (FAC). This study compares these two regimens with regard to response and survival. METHODS: The records of all @entity1 presenting between January 1973 and December 1991 with a stage IIIB (T4d, any N, MO) @entity0 with proven dermal lymphatic invasion by @entity5 cells were reviewed retrospectively. RESULTS: The study comprised 38 @entity1 ; 28 received CMF (22 CMF, 6 CMF/VP), and 10 received FAC. The overall response rate to induction chemotherapy in the CMF/VP group was 57% (40% PR, 17% CR), and 100% (60% PR, 40% CR) in the FAC group. The median overall survival for @entity1 receiving CMF/VP was 18 months compared with 30 months for @entity1 receiving FAC (p = 0.02). The median disease-free survivals for the CMF/VP and FAC groups were 6 and 24 months, respectively (p < 0.001). When comparing responders and nonresponders with CMF/VP induction therapy, the responders had a significantly longer overall median survival (24 versus 10 months) (p < 0.001) and disease-free median survival (8 versus 2 months) (p < 0.001). All of the five @entity1 remaining alive received FAC with 80% (four of five) having a complete response. These four @entity1 subsequently underwent mastectomy and radiation. CONCLUSION: This study suggests that a @entity632 -containing chemotherapy regimen improves overall and disease-free median survivals when compared with the previously used CMF combination in the treatment of @entity0 . A favorable response to induction chemotherapy also appeared to be associated with an improved survival.
